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Background:  
Systemic Lupus Erythematosus is one of the common illnesses in a 
Rheumatology department. It affects mostly women in the reproductive age 
group. Few decades back it was a disease with high mortality. There has been 
an increasing understanding on the etio-pathogenesis of this disease. 
Improved investigations and treatment modalities have improved the survival 
of these patients significantly. Most of this data is from developed countries. In 
view of the difference in background health of the population, differences in 
availability of health care, and genetic differences the survival needs to defined 
for an Indian population in an Indian setting. This study attempts to do this, 
particularly because the information from India regarding his is limited.  
Methods: 
A cohort of225 patients admitted in CMC from 2007 to 2010 were assessed for 
their duration of survival since diagnosis. This group of patients had their 
various parameters documented during the admission in their history, 
examination, investigations and treatment. This was retrieved onto an excel 
sheet from the clinical work station. These patients were followed up during 
their review visits in the outpatient or inpatient setting as the case may be. 
A Kaplan Meir survival curve was made for these patients. Their significance of 
correlation with any of the clinical or laboratory indices were evaluated by log 
rank test. The same group of patients was also assessed for evidence of organ 
damage.  
Results:   
The survival of our patients at 1-,3-, 5-, 10- and 15- years were 97.6%, 
95.6%,93.8%, 83%  and 83% respectively. This survival rate is comparable with 
survival from developed countries for up to 5 years. At 10 years our survival is 
less than developed countries. The survival rate is better than previous data 
from India which was from one to two decades back. 
 Other than the number of criteria fulfilled for the diagnosis (The 1997 update 
of the 1982 revised ACR classification criteria for SLE), and use of 
Mycophenolate, Azathioprine or Cyclophosphamide none of the other 
parameters showed a significant correlation with survival in our study.  
The mean survival time of the SLE patients with these different parameters are 
also calculated in this study. 
The median duration of symptoms before a diagnosis was made for our cohort 
was 6 months, with 25 percentile having a diagnosis at 3 months and 75 
percentile having a diagnosis at 18 months. 
The common organ damages were cataract, seizures, end stage renal disease 
and diabetes mellitus. 
Conclusion:  
1. The five year survival of our south Asian cohort of SLE patients is 95.6% 
which is comparable with other published international cohorts. 
There is an improved survival of SLE patients in this south Asian cohort 
compared to previously published literature from the subcontinent  
2. The ten year survival of our cohort is 83% which is better than all 
previously published cohorts from south Asia, but is less than other 
cohorts from the developed world. 
3. The commonest organ damage or its manifestations in our cohort of 
patients is seizures followed by diabetes mellitus, end stage renal 
disease and cataract in decreasing order of frequencies. 
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Aim 
To find the survival rate and end organ damageof systemic lupus erythematosus 
patients of a South Asian population, in a developing country. 
Objectives 
• Find the survival pattern of a South Asian cohort of SLE patients in India. 
•To identify factors that could influence the duration of survival   
•Estimate the prevalence of permanent organ damage over different periods of  
timein this cohort of patients. 
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Introduction 
Systemic Lupus Erythematosus (SLE) is one of the commonest disease entity with 
which patients come to any Rheumatology department. The other illnesses with 
which patient commonly reach the Rheumatologist are 
Seronegativespondyloarthropathy, Sjogren’s syndrome, other connective tissue 
diseases (viz. Rheumatoid arthritis, Scleroderma, Mixed Connective Tissue 
Disease, Inflammatory myositis), fibromyalgia, Crystal arthropathies, etc.  
SLE is a disease predominantly of women, more so in the reproductive age group. 
In view of this nature of the time of life during which the disease starts and 
progresses, it has tremendous implications on the individual, the family and the 
society at large. The disease has been known for more than a century, and there 
are treatment modalities available for the disease for more than half a century. 
With major advances in the field of immunology, molecular biology and genetics, 
there has been a better understanding of the disease. Still there is a lot to be 
revealed on the etiopathogenesis of the disease and hence its management. 
 In the current scenario, the available treatment options have improved the 
quality of life and longevity of patients with the disease significantly. SLE being a 
multisystem disease, can have mucocutaneous , musculoskeletal, 
4 
 
neurological,psychiatric, cardiovascular, renal, hematopoietic,  gastrointestinal , 
reproductive system, ophthalmic or  pulmonary manifestations. This is 
compounded by the comorbidities due to the nature of the disease like infections 
and metabolic complications. Added to this are the effects of various treatment 
modalities on the different organ systems.In view of this the disease is very 
heterogeneous in its clinical presentation and profile. This would also mean the 
severity of the disease, the organ systems affected, the treatment required varies 
between individual patients.  
In view of the multisystem nature of the disease, at the level of secondary or 
tertiary care patients with SLE could present to various specialties common ones 
being internal medicine, nephrology, dermatology, hematology or neurology in 
addition to Rheumatology. In a developing country like India where the health 
care is not generally well streamlined the approach to an individual patient may 
vary. Hence the outcome for the individual patient also depends on the expertise 
of the individual treating physician and health care team.  This is compounded by 
the need for a multispecialtyset up and more sophisticated investigations at least 
for some patients. As for any other illness, the mortality and morbidity of SLE is 
also influenced by the background morbidity and mortality in the community. This 
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in turn in a wider perspective is a reflection of the health care status of the 
community or country as the case may be. 
Huge strides made in public health, availability of medical care and individual 
disease treatment has improved the outcome of many diseases including SLE. In 
spite of this there is long way to go before an optimum care of disease for all is 
achieved. As with many other diseases over the last three to four decades, for 
many patients, SLE has changed from an acute life threatening disease to a 
chronic illness requiring long term medical care including follow up, investigations 
and medications. This in turn has brought in issues of marriage, pregnancy, 
employment and employability. All these have social and financial implications on 
the individual, family and health care providers. 
The Indian Scenario 
Etiologically SLE has a strong genetic and environmental background. This in itself 
would mean that the behavior and outcome of the disease in India could be 
different from that of other ethnic, geographic and cultural groups. The rapid 
recent advances in medicine and great differences in availability and organization 
of health care between countries would mean that the inferences from one set of 
population need not necessarily be true for another population. This would mean 
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that to know about the behavior and outcome of Indian patients with SLE, we 
would need Indian data and inferences. 
India being an ethnicmosaic would mean that there could be significant genetic 
differences within the population and hence the profile of diseases with a genetic 
basis. In addition to this are the economic differences within the population, 
which will affect the outcome of a disease particularly when the payment for 
medical treatment is at the point of care. Compounded to these factors is the 
wide divide in access to health care - urban vs rural or between the different 
states in India. 
With regards to SLE there are few centers in India with specialized services 
catering to this group of patients. 
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Christian Medical College (CMC) Scenario 
In CMC, SLE patients are predominantly managed by the Rheumatology 
department with inputs from Nephrologist, Radiologist, Intensivist, Infectious 
disease and other specialist as appropriate. Internal Medicine and Nephrology 
also manage SLE patients independently with input from Rheumatologist if 
required. 
In terms of number of SLE patients we probably have one of the largest, 
anywhere in the world. Our patients are from a varied socioeconomic 
background. Geographically we have patients predominantly from South and 
Eastern India. We also get few patients from North and Western India, 
Bangladesh, Nepal, Bhutan and Maldives. 
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Justification for the study 
There is very little data from India on the survival of SLE patients in India. Even the 
available data is reasonably old and hence may not reflect the current Indian 
situation on survival of SLE patients. There have been many changes in the health 
scenario in India which warrants evidence on the current scenario of SLE survival. 
India with its own unique ethnic, socio-economic and health care set up need to 
have information from our country to be meaningful to our patients. Mere 
extrapolation of data from other countries will have its own shortcomings. 
Christian Medical College, Vellore being one of the major centers of 
Rheumatology in India and South Asia and has probably the largest cohort of 
patients with SLE, particularly so in the department of Clinical Immunology and 
Rheumatology in the institution. This information will be the closest available data 
on the survival of SLE patients in India. This could be used to prognosticate the 
SLE patients reaching a hospital in the country. 
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It would be useful, if possible to know the features at any given point which 
would help us to identify patients with a poor survival in terms of mortality and 
end organ damage. 
For any disease, in addition to mortality one important aspect of interest to the 
patient and the health care team would be the morbidities due to the disease. 
The morbidities have a major impact on the quality of life for the patient and their 
careers, their family, the need to accesses health care, the cost of health care. 
Two major factors that determine morbidity in SLE are acute illnesses and 
permanent organ damage. The acute illnesses could be due to increased disease 
activity also called a disease flare, acute organ damage orassociated 
complications like infections. Some possibilities of acute organ damage are 
pulmonary embolism, acute myocardial infarction, lupus celebrities, acute lupus 
nephritis etc. some of these being reversible. 
The irreversible damages to the organ system – the permanent damages are 
major cause of morbidity and ads on to the mortality by themselves. These 
damages could be due to the disease itself or a complication of treatment for the 
disease. Cataract for example can be caused by steroid intake. 
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Seizures could be due to secondary antiphospholipid antibody syndrome in SLE, 
or cerebral involvement due to SLE. Persisting proteinuria more than 3.5 gm% or 
persistently raised creatinine are indicators of permanent renal damage. 
Cardiac damage can manifest as angina pectoris or myocardial infarction. This can 
be due to the inflammatory nature of the disease per se or long term steroid use. 
Osteoporosis and osteoporotic fracture can be due to steroid use. Avascular 
necrosis can be caused by secondary antiphospholipid antibody syndrome or long 
term steroid use. Another complication of long term use is steroid induced 
diabetes mellitus. It is known that there is an increased incidence of malignancy in 
SLE compared to age matched controls. 
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Review of literature 
Diagnosis of SLE 
SLE is a multisystem systemic autoimmune disease, with different systems 
affected to varying extent in each patient. One of the preliminary 
requirements for a study on SLE would be defining the patients. The 
diagnosis of SLE is based on classification criteria.  
The classification criteria for a diagnosis of SLE have evolved from the early 
1950’s to the second decade of the 21 st century. 
The American Rheumatism Association developed the first classification 
criteria in 19711. This criteria was revised and published in 19822.This 
criteria has 11 elements, a patient had to fulfill 4 out of the 11 in ordered to 
be labelled as SLE. 
This criteria was revised in 1997, by the American college of Rheumatology 
(ACR) and is known as the “The 1997 update of the 1982 revised ACR 
classification criteria for SLE.”3 
In 2012, to include the new knowledge in the understanding of SLE, the 
Systemic Lupus International Collaborating Clinics (SLICC) group revised and 
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validated the ACR classification criteria called the “SLICC classification 
criteria for SLE”. 
In the SLICC classification criteria for SLE, 17 criteria are identified. 
This criterion has a sensitivity of 94% and a specificity of 92%4. The patient 
must satisfy 4 criterion, including at least one clinical and one 
immunological criterion or the patient must have biopsy proven lupus 
nephritis with Antinuclear antibodies (ANA) or anti-double stranded DNA 
antibodies4 (Annexure II). 
In our study cohort all the patients had a diagnosis of SLE made before 
2012 and hence the 1997 update of the 1982 revised ACR classification 
criteria for SLE was used. This criterion has 86% sensitivity and 93 to 96% 
specificity5. 
One of the limitations of the use of this criterion would be limited detection 
of mild cases of SLE, or new cases in the early stages of the disease6 
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Survival statistics 
In an ideal world, to determine the survival of patients with SLE, the general 
population should be surveyed for SLE and cases should be picked up right from 
the onset. The people affected and unaffected from SLE should be subsequently 
be followed up for health events and compared. This is a difficult and costly 
proportion7. 
Since this would not be a practical proposition, patients diagnosed with SLE can 
be subsequently followed up and their health events recorded up to death and 
this can be compared with a population matched for other variables which can 
influence health events. Even in this scenario, patients differ greatly in the length 
of time and severity of disease they have had before the diagnosis. There are 
multiple factors which could affect the outcome of the disease other than the 
biological factors connected to the disease. General quality of health in the 
background population, health seeking behavior in the population, quality and 
availability of health care, socioeconomic status, comorbid illnesses are some 
important ones among them. These limits the ability to generalize the 
observations derived from a given disease population. But the information 
derived from a specific clinic will be useful in evaluating its own outcome in 
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managing patients7. When a life table for survival analysis is made, two important 
issues to addressed are 
(i) Definition of the starting point – in this study this is the point of 
diagnosis of SLE. 
(ii) Length of follow up for those lost to observation, those still alive and 
under study, those who have died. 
The commonly used methods for survival analysis are the life table, 
Kaplan-Meir, log rank and Cox model. 
 
The analysis of the follow up of patients over long term is done in terms of a life 
table. From the life table, the proportion of patients surviving to various times 
since diagnosis is an important index of survival ie.thesurvival rate at specific 
times. Other method is to make the survival curve which is based on the 
percentage of people existing at various time points. For duration of survival the 
median survival durationcan be used for survival analysis. If less than 50 percent 
of the observations are uncensored and the largest observation is censored, the 
median survival time cannot be estimated, but the mean survival time is 
calculated8. 
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The survival patterns help patients and treating physicians to ascertain what to 
expect in specific group of patients. 
In survival analysis when the exact starting point of a disease is not known it is 
called left censoring. When the end time of the disease is not known it is called 
right censoring. In survival analysis one of the assumptions made is that survival 
pattern of those recruited at any time into the study are same. It is also assumed 
that different subgroups (eg. Socioeconomic status) have similar survival pattern. 
If the survival pattern is not similar they should be studied separately. 
Kaplan-Meir6 
  In this method of survival analysis is used when the patients are observed 
continuously and the exact duration of reaching the end-point or the time of 
dropout is known. The dropouts are considered in the analysis till the point of 
dropout and for the analysis after that they are not included. The proportion 
surviving at each unique time point is calculated from those patients available at 
that time point. 
Ideally continuous observations of is to be used. In this way the exact time of 
survival or dropout is known for each patient. When the numbers of subjects are 
large periodic observations would be cost effective. 
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The plot of survival against time is called survival curve. The survival curve can be 
used to find the median survival time, quintiles and other measures of survival 
distribution. 
 
Causes of mortality in SLE  
SLE being a multisystem disease and predisposed for several comorbidities due to 
the disease itself and adverse events due to medications; finding out the exact 
cause of death in a given patient may be difficult. Before the middle of the 
twentieth century when there was no effective treatment for SLE, progressive 
disease activity and its complications was one the commonest cause of death in 
SLE10. 
In the current scenario where the understanding and treatment of SLE has 
improved by leaps and bounds, severe lupus disease activity, infection, renal 
disease and cardiovascular disease are important causes of death in SLE. The 
survival rate of SLE has improved from less than 50% at 5 years to 92 – 98%  in the 
first decade of this century as shown in the table from clinical and experimental 
rheumatology 2008;26(Suppl. 51) S 72 – 79 
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Study Year No.ofpat
ients 
Location Survival 
% 5 Yrs 
Survival 
%10 Yrs 
Survival 
%15 Yrs 
Survival 
%20 Yrs 
Al-Saleh 2008 151 UAE 94 NA NA NA 
Cervaria 2003 1000 Europe 95 92 NA NA 
Doria 2006 207 Italy 96 93 76 NA 
Funauchi 2007 306 Japan 94 92 NA 77 
Heller 2007 92 Saudi Arabia 92 NA NA NA 
Kasitanon 2006 1378 USA 95 91 85 78 
Mok 2005 285 China 92 83 80 NA 
Sun  2008 100 China 98 98 NA NA 
Wadee 2007 276 South Africa 52-72 NA NA NA 
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Despite this SLE patients have a 2.4 to 3 fold increased risk of death compared 
with the general population9.Lupus has a bimodal pattern of mortality9. 
Early mortality (< 1 Yr.) is due to severe disease activity and late mortality due to 
complications of long standing disease and treatment related complications. 
 
Reasons for improved survival 
Overall improvement in mortality in the general population has its impact on SLE 
as well. The table below shows the World Health Organization data on the 
survival of the general population in India in comparison to other developed 
countries. 
In addition to the overall improvement in medical care, availability of antibiotics, 
antihypertensive, renal replacement therapy and the appropriate use of steroids, 
antimalarials and other immunosuppressive medications have improved survival 
of SLE patients 
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Mortality studies – and survival data    
International data 
The five year survival of SLE was 50% in 19557. Currently the 5 year mortality is 
reported at 95%11. As discussed previously, part of this improvement is related to 
the improvement in health and survival of the population in general. Most of the 
data on the survival is from developed countries. Hence it is hard to judge the 
mortality in developing countries including India. 
In addition to this is the fact that the average life expectancy in India is very 
different compared to North America or Europe. 
According to the WHO data published in April 2011 life expectancy in India is: 
Male 63.8, female 67.3 and total life expectancy is 65.5 which gives India a World 
Life Expectancy ranking of 13312. 
In North America and Europe the average life expectancy is around 80years.Even 
though there is contribution from high infant mortality in India, the life 
expectancy in India currently is less than what prevailed in the developed 
countries 20 years back12. In addition to this fact is that non-Caucasians have a 
higher mortality in SLE compared to Caucasians.  
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                                        Life Expectancy at birth in Years12 
Country Years Male  Female Both sexes 
 
      India 
2011 64 67 65 
2000 60 63 61 
1990 58 59 58 
 
United 
Kingdom 
2011 79 82 80 
2000 76 80 78 
1990 73 79 76 
 
United States 
of America 
2011 76 81 79 
2000 74 80 77 
1990 72 79 75 
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Indian survival data 
There have been 3 published data on survival of SLE patients in India.  
The first one was by Dr.  Malaviya AN, Dr. Misra R et al from All India Institute of 
Medical Sciences, New Delhi in 1986 in Rheumatology International. This showed 
a five year survival of 68% and 10 year survival of 50% during the period 1981 to 
198513. The same centre with Dr Ashok Kumar, Dr. Malaviya AN et al Published 
survival data from 1986 to 1990 in Rheumatology International in 1992 which 
showed a similar outcome with no statistically significant improvement or any 
trend towards improvement compared to the previous 5 years14. 
The third article was published from Christian Medical College, Vellore in the 
National Medical Journal of India in 1997 by Murali R, Jeyaseelan L, John L and 
Ganesh A. The cumulative percentage survival at 1,5 and 10 years was 89%, 77% 
and 60% respectively. The Markov chain predicted a life expectancy of 13.9 
years15. 
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SLE Survival in other Asian countries 
There have been studies which suggested that Asian patients have more organ 
involvement and mortality than Caucasians16. 
There have been other studies suggesting corrected for accesses to health care 
and socioeconomic status, the organ damage and mortality are comparable to 
Caucasians17. 
In a study published in Lupus 2011, among the Hong Kong Chinese, the 5 and 10 
year cumulative survival of SLE patients was 92 and 83% respectively.In this study 
renal damage was the most frequent disease related damage and musculoskeletal 
damage the commonest treatment related complication. 
In this same paper an analysis of 514 SLE deaths showed that the most common 
cause of death was Infection (22%) others being cancer 10%, Cardiovascular (9%), 
Cerebrovascular (5%), complications and renal failure (7%)18. 
In a previous study published in Rheumatology, in 2000, by the same group about 
mortality 186 patients were studied, diagnosed between 1992 and 1999. 
The 3-, 5-, and 7- year survival were 97, 93, and 93% respectively19. 
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SLE survival in other South Asian countries 
A retrospective review of the survival rate of 198 SLE patients was published in 
Lupus 2009 from the Aga Khan University Hospital, Karachi, Pakistan. The 
diagnosis of SLE was made between 1992 and 2005. This review showed survival 
rates of 3-, 5-, 10-, 15-, 20- year of 99, 80, 75, and 75% respectively. In this study, 
a multivariate analysis revealed renal disease was an independent risk factor for 
damage. By cox regression analysis it was seen that renal involvement and 
infection were independent risk factors for mortality. 
In this analysis it was also shown that the mean duration of symptoms was 2.8 
years before a diagnosis of SLE was made20. 
 
Damage in SLE  
Death late in the course of SLE is due to accrued damage from the disease, its 
treatment and other co-morbidities21. 
The disease activity, particularly with respect to individual organs can result in 
specific organ damage and dysfunction. This results in increased morbidity. 
Thus the treatment of SLE focuses not only on preventing death but also reducing 
morbidity from the disease or its therapy. 
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Assessment of organ damage 
In 1996 the SLICC group along with ACR, developed the SLICC/ACR Damage Index 
(SDI)22. The SDI assesses the damage in 12 body systems after onset of SLE. The 
SDI includes 41 items that could indicate organ failure.,etc . The damage should 
be present for at least 6 months to be included in the SDI. The SDI is shown in 
annexure III.The damage is an independent outcome measure. 
 
Indicators of Organ damage 
The indicator of damage includes cataract, seizures, Proteinuria ≥ 3.5 g/day, renal 
failure, angina, myocardial infarction, osteoporosis with fracture or vertebral 
collapse, avascular necrosis, diabetes, malignancy. 
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Methodology 
225 SLE patients who were admitted in the wards (Inpatients) of CMC, Vellore 
during the years 2007, 2008, 2009 and 2010 were recruited into the study. The 
clinical details and laboratory investigations of these patients at the time of 
admission were entered in the Excel sheet from their discharge summaries in the 
clinical work station. 
The Clinical Work Station is a computer based application in which the patient data is 
entered and can be reviewed. In this patient data and patient’s reports like the discharge 
summary can be reviewed comprehensively. 
 These patients are being followed up in the department of Clinical immunology and 
Rheumatology, at varying intervals of time ranging from three monthly to two yearly. 
During the follow up visits these patients are assessed for disease activity and any organ 
damage. Clinical history, clinical physical examination and appropriate laboratory 
investigations are done towards this. 
These patients are on different immunosuppressive medications which include steroids, 
hydroxychloroquine, cyclophosphamide, azathioprine or mycophenolate in different 
doses. The use of these medications could influence the survival and organ damage. 
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Background of patients 
All these patients are from India, Bangladesh or Maldives visiting CMC Vellore for 
medical care. 
The patients were recruited if they fulfill the 1997 update of the 1982 revised ACR 
classification criteria for SLE. They were recruited irrespective of the severity of the 
disease or specificity of indication for admission. 
Setting: 
These patients were followed up in the outpatient clinics of the Clinical Immunology and 
Rheumatology department or as inpatients, if they have been admitted at the time of 
review, based on the clinical condition. SLE patients on follow up, but not part of the 
cohort were not included in the study.  
This was a cross sectional study followed up as a cohort 
Details of Research method: 
The participants of the study have a history, clinical examination and regular blood 
investigations done at the review visit. Each patient was assessed for organ damage. For  
patients who could not be seen on a specific follow up visit, the  
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outpatient scanned charts were screened for evidence of damage indices viz. cataract, 
seizure, proteinuria more than 3.5 gm/day, end stage renal disease, angina 
pectoris/angioplasty, myocardial infarction, osteoporotic fracture, avascular necrosis, 
diabetes mellitus or malignancy. These findings are recorded from the Clinical research 
form on to an excel sheet. These damages were recorded for 1-, 3-, 5-, 10-, and 15- years 
since diagnosis. 
Each of these participants who have completed 1-, 3-, 5-, 10-, and 15- years are 
evaluated for a correlation between the survival and different parameters at 
admission including different forms of treatment. 
For those patients for whom the last visit was more than 6 months before the 
time of analysis were contacted over the phone (mobile or land line) with regards 
to their survival status. The phone numbers were obtained from the hospital 
medical records of the patients. 
With regards to damage indices the percentage of patients with permanent 
damage as indicate by the different parameters, at the end of 1-, 3-, 5-, 10- and 
15-years are also calculated. 
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Details of data analysis  
The data was initially entered into a Microsoft excel sheet. From this it was 
transferred to SPSS 16.0 and the analysis was done on SPSS 16.0.  
The two, three, five, ten and fifteen year survival is calculated from a Kaplan-Meir 
survival curve created from this data.This curve can be used to calculate median 
survival rate at these number of years as well. Comparison of survival curves for 
different parameters were done using the log rank test.  
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Results 
In our study 225 patients, who were admitted in Christian Medical College, 
Vellore between the years 2007 to 2010 were included. All of them fulfilled the 
1997 update of the 1982 revised ACR classification criteria for SLE. 
 
Gender distribution 
Of these 208 (92.4%) were female and 17 (7.6%) were male. 
 
 
 
 
 
 
208(92%)
17(8%)
0, 0%, 
Sex distribution
Female Male
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Median duration of symptoms before diagnosis 
Of the 225 patients, we had complete information on the exact time of onset of 
symptoms contributing to a diagnosis of SLE and the time of diagnosis of SLE for 
165. In the remaining 60, the exact timing of onset of symptoms was not 
available. 
The Median duration of symptoms before a diagnosis of SLE was made was 6 
months with a range of 0 to 183 months. 
The 25 th percentile was 3 months and 75 th percentile was 18 months.
  
Median interval between onset of symptoms and diagnosis 
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Deaths 
The total numbers of deaths recorded in the 225 patients were 17, during the 
follow up period. 
 
 
Survival analysis 
 A Kaplan Meyer curve on survival analysis showed that the one year survival rate 
was 97.6%, the three year survival was 95.6%, five year survival rate was 93.8%, 
and the 10 and 15 year survival was 83%. 
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Survival curve for 15 Years 
 
 
 
 
 
 
 
The mean survival period in SLE for our cohort of patients is 253.44 months with a 
standard error of 10.26 and 95% Confidence interval between 233.33-273.54 . 
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Survival at 10 Years 
In view of the very few patients at the 15thyear follow up, the 15 year follow up 
may not be truly representative. 
In view of increased censoring of values at 120 months (10 years), the survival 
curve for 10 years alone is taken and shown below 
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In view of the very few patient data available for survival beyond 10 years, the 
mean survival was calculated for 10 years. The mean survival period in SLE for our 
cohort of patients is 107.52 months with a standard error of 2.61 and 95% 
Confidence interval between102.40-112.64. 
 
We tried to look at the different factors which could predict difference in survival.  
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Gender and Survival 
 
 
 
 
 
  
0-Male   1- Female 
There were two deaths among the male patients and 15 deaths among the 
female patients. 
The mean survival time for men was 151 months (SE-19.7, 95% Confidence 
Interval 112.45-189.83) while for women this was 258.04 months (SE-9.3, 
95% Confidence Interval 240-276).    This was not statistically 
significant.The p value was 0.734 [Log Rank (Mantel-Cox)]. 
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ACR Criteria and Survival 
 
By Log rank (Mantel-Cox), there was a significant correlation between the 
number of ACR criteria fulfilled at diagnosis with a p value of 0.008. 
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S. creatinine at admission and survival 
 
 
The mean survival of the patients with a raised creatinine (>1.4 mg%) was 255.35 
months (SE-11  ,95% Confidence interval 233.8 – 276.9) while that for a creatinine 
< 1.4 was 121.15 months (SE-8.9  ,95% Confidence interval 103.7 – 138.6). The p 
value was 0.209 [Log Rank (Mantel-Cox)], which is not significant. 
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Lupus Nephritis and survival 
 
 Of the 211 patients 132 had lupus nephritis while 79 did not have lupus nephritis. 
There were 9 deaths in those with lupus nephritis and 8 in those without lupus 
nephritis.  
 
The mean survival of the patients with lupus nephritis was 258.18 months 
(Confidence interval 233.8 – 283.08) while for those without lupus nephritis was 
196.39months (Confidence interval 174.38 – 218.4). The p value was 0.43 [Log 
Rank (Mantel-Cox)], which is not significant 
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13
28
23
51
15 2
Lupus Nephritis No. Total 132
Not biopsied
Class 2
Class3
Class 4
Class 5
Class 6
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The mean survival time for the class of Lupus nephritis is shown below 
       Mean Survival time 
(Months) 
           SE; 95% CI 
Class II (n=28 )                        79     9.9; 60-99 
Class III & 
IV(n=74) 
                       63    5.3;  53-74 
Class V (n=15)                        90    21.6; 48-133 
Class VI (n=2)                        53    51.5;   0-153 
 
These differences are not statistically significant 
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Class II Lupus Nephritis 
There were 28 patients with Class II lupus Nephritis. 9 of them were treated with a 
second line agent while 19 were not treated with a second line agent. There were 2 
deaths in the group without second line agent, none in the group with second line 
agent. The difference survival is shown in the graph below, but this is not 
statistically significant. [p 0.495 log rank (Cox-Mantel)] 
 
 
 
 
 
 
 
 
.00 Lupus nephritis with second line agent 
3  Lupus nephritis without second line agent 
43 
 
Neuropsychiatric lupus and survival 
21 patients had CNS lupus of which 2 died, while 189 did not have CNS lesions 
among them 15 died. 
The mean survival time for patients with CNS lupus was 142 months  (SE 23;95% 
Confidence Interval 97-187) while for those without CNS lupus is 258 months (SE 
9;95% Confidence Interval 241-276).This was not statistically significant.The p 
value was  0.725 [Log Rank (Mantel-Cox)]. 
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Secondary antiphospholipid antibody syndrome (APS) and survival 
30 patients had antiphospholipid antibody syndrome while 178 did not have, 3 of 
the former died while 14 of the latter group.  
The mean survival time for patients with APS is 119 months (SE 11;95% 
Confidence Interval 231-275) while for those without APS is 253 months (SE 
11;95% Confidence Interval 231-275). This was not statistically significant. 
The p value was0.514 [Log Rank (Mantel-Cox)]. 
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Survival with either cyclophosphamide or azathioprine or Mycophenolate 
There were 83 patients who were on either cyclophosphamide or azathioprine or 
mycophenolate. There were 128 patients who were not on any of these at the 
time of admission. There were 3 deaths in the group on any of these second line 
agents, and 14 in the group not on second line agent. 
Mean survival:Patients on a second line agent- 277 months (SE 6.6; 95% CI  264.4 
to 290.3)Patients not on second line agent – 193 months (SE 11.2; 95%   CI 170.8 
to 214.8).This difference was statistically significant with a p value of 0.056 [Log 
Rank (Mantel-Cox)] 
 
 
 
 
 
1.00 Survival in patients with cyclophosphamide or mycophenolate or azathioprine 
0.00 Survival in patients without a second line agent. 
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Organ damage at different time points  
 
SDI 1 Year 3 Year 5 Year 10 Year 15 Year 
Cataract 
Seizure 
Proteinuria (3.5gd) 
ESRD 
Angina/CABG/Plasty 
MI 
Osteoporosis 
AVN 
DM 
Malignancy 
3/183(1.7) 
17/186(9.1) 
1/182(0.5) 
6/185(3.2) 
1/183(0.5) 
0(0.0) 
0(0.0) 
3/182(1.6) 
10/185(5.4) 
0(0.0) 
4/144(2.8) 
14/150(9.3) 
1/149(0.7) 
2/149(1.3) 
0(0.0) 
2/149(1.3) 
0(0.0) 
6/148(4.1) 
9/150(6.0) 
0(0.0) 
5/111(4.5) 
8/116(6.9) 
0(0.0) 
6/116(5.2) 
0(0.0) 
1/114(0.9) 
0(0.0) 
6/114(5.3) 
7/115(6.1) 
0(0.0) 
1/26(3.8) 
4/27(14.8) 
0(0.0) 
3/29(10.3) 
0(0.0) 
1/26(3.8) 
1/26(3.8) 
0(0.0) 
4/26(15.4) 
1/26(3.8) 
0(0.0) 
0(0.0) 
0(0.0) 
0(0.0) 
0(0.0) 
0(0.0) 
0(0.0) 
0(0.0) 
1/11(9.1) 
0(0.0) 
 
 
47 
 
Cumulative damage at various time points 
 
SDI 1 Year 3 Year 5 Year 10 Year 15 Year 
Cataract 
Seizure 
Proteinuria (3.5gd) 
ESRD 
Angina/CABG/Plasty 
MI 
Osteoporotic fracture 
AVN 
DM 
Malignancy 
3 
17 
0 
6 
1 
0 
0 
3 
10 
0 
 6 
24 
1 
8 
1 
2 
0 
6 
13 
0 
9 
24 
2 
12 
1 
2 
0 
7 
14 
0 
10 
26 
2 
13 
1 
3 
0 
0 
16 
1 
10 
26 
2 
13 
1 
3 
1 
0 
17 
0 
 
The commonest complication all thru the 10 years in our cohort of patients is 
Seizures. This is followed by diabetes mellitus, end stage renal disease and 
cataract. 
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Discussion 
The following table shows a comparison of the survival data from our current 
study to the previous study from CMC, Vellore; All India Institute of Medical 
Sciences over two time periods; the Other South Asian study from Karachi, 
Pakistan and study from Hong Kong China.  
 Our study 
(1994-
2014) 
CMC, 
Vellore15 
(1981-’93) 
 
AIIMS13 
(1981-‘85) 
 
AIIMS14 
(1986-’90) 
 
Pakistan20 
(1992-‘05) 
China18 
 (1999-‘08) 
No. of 
patients 
 225 98 123 163 198 285 
1 Year   97.6%  89% NA NA NA NA 
3 Year   95.6% NA NA NA 99% NA 
5 Year   93.8%  77% 68% 68% 80% 92% 
10 Year   83 %  60% 50% 50% 75% 83% 
15 Year   83% NA NA NA 75% 80% 
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In our study the univariate analysis showed that the correlation was significant 
only between the number of ACR criteria fulfilling for the diagnosis of SLE and 
survival. 
There was also a significant correlation between use of Mycophenolate or 
Cyclophosphamide or Azathioprine and survival compared to nonusers. 
Comparison with CMC Vellore study15 
This study published in 1997, shows a survival less than our current study for all 
three years (1-,3-,and 5 Years). 
The possibilities for the improvement in the survival could be 
i. General improvement in the health indices in India as a whole. 
ii. Improvement in care of patients with SLE in CMC itself 
iii. During the previous study from CMC, SLE patients were managed in the 
General Medicine units, while in the current study all these patients were 
managed in the Clinical Immunology and Rheumatolgy unit. 
iv. Availability of better aminities to treat complications  
v. More widespread use of drugs like hydroxycholroquine andmore use of 
Mycophenolate for organ involvement. 
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Comparison with AIIMS study13,14 
 Both the studies from AIIMS, are approximately 20 years back. There is major 
difference in the availability of health care in India during this period. There is 
considerable improvement in expertise and options of treatment for SLE available 
in India during this period. This could explain the significant improvement in 
survival in our study. 
Comparison with Other South Asian Study20 
The study period of this study from Pakistan is closer to our study. The five and 
ten year survival is better in our cohort compared to the cohort from Karachi.The 
incidence of cataract and diabetes mellitus in our cohort of patients are more 
than the other cohort from Pakistan as well. 
Comparison with study from Hong Kong China5 
The 5, 10 and 15 year survival in our cohort is comparable to this Chinese 
cohort.In comparison to the organ damage in the southern Chinese cohort of 
patients, diabetes mellitus and cataract are  more common in our cohort than 
theirs. The CNS and renal damages were comparable.  
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Conclusion 
 
1. The five year survival of our south Asian cohort of SLE patients in India at 
CMC, Vellore is 95.6% which is comparable with other published 
international cohorts. 
There is an improved survival of SLE patients in this south Asian cohort 
compared to previously published literature from the subcontinent  
 
2. The ten year survival of our cohort is 83% which is better than all previously 
published cohorts from south Asia, but is less than other cohorts from the 
developed world. 
 
3. With improved survival of SLE patients the number of patients with SLE 
requiring medical care will be on the rise. 
 
4. The commonest organ damage or its manifestations in our cohort of 
patients is seizures followed by diabetes mellitus, end stage renal disease 
and cataract in decreasing order of frequencies. 
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Annexure I 
Clinical Research form- SLE Survival Analysis and Damage Indicators 
 
Serial no. 
 
Demographics 
Name:      Hospital number: 
Age:       Sex: 
 
Disease 
Date of first symptom: 
Date of diagnosis of SLE: 
Date of admission in CMC: 
SLEDAI at admission: 
SLEDAI at review: 
Survival time in months: 
Treatment regime                                         Dose                                                 Duration 
Steroid 
Deflazacort 
Prednisolone 
 HCQ 
          Cyclophosphamide 
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Mycophenolatemofetil 
Mycophenolate sodium 
          Azathioprine 
          Cyclosporine 
          Aspirin 
          Warfarin 
Acetrome 
 
SLICC/ACR 
         Cataract 
         Seizures 
         Proteinuria > 3.5 gm% 
         Angina 
         Myocardial Infarction 
         Osteoporosis with fracture 
        Avascular necrosis 
        Diabetes Mellitus 
        Malignancy 
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Annexure II 
System Lupus International Collaborating 
Clinics/American College of Rheumatology 
Damage Index for Systemic Lupus Erythematosus* 
 
   Item          Score 
 
Ocular (either eye, by clinical assessment) 
 Any cataract ever         1 
 Retinal change or optic atrophy       1 
Neuropsychiatric 
 Cognitive impairment (e.g. memory deficit, difficulty with   1 
calculation, poor concentration, difficulty in spoken or written 
 language, impaired performance levels) or major psychosis 
 Seizures requiring therapy for 6 months      1 
 Cerebrovascular accident ever (score 2 > 1)      1 (2) 
 Cranial or peripheral neuropathy (excluding optic)     1 
 Transverse myelitis         1 
Renal 
 Estimated or measured glomerular filtration rate<50%   1 
 Proteinuria >3.5 gm/24hours        1 
 Or 
 End-stage renal disease (regardless of dialysis or transplantation)  3 
Pulmonary 
 Pulmonary hypertension (right ventricular prominence, or loud P2)  1 
 Pulmonary fibrosis (physical and radiograph)     1 
 Shrinking lung (radiograph)        1 
 Pleural fibrosis (radiograph)        1 
 Pulmonary infarction (radiograph)       1 
Cardiovascular 
 Angina or coronary artery bypass      1 
 Myocardial infarction ever (score 2 if > 1)     1(2) 
 Cardiomyopathy (ventricular dysfunction)     1 
 Valvular disease (diastolic murmur, or systolic murmur >3/6)   1 
 Pericarditis for 6 months, or pericardiectomy    1 
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Peripheral vascular 
 Claudication for 6 months        1 
 Minor tissue loss (pulp space)       1 
 Significant tissue loss ever (e.g. loss of digit or limb)(score 2 if > 1  1(2) 
site) 
 Venous thrombosis with swelling, ulceration, or venous stasis   1 
Gastrointestinal 
 Infarction or resection of bowel below duodenum spleen, liver, or  1(2) 
 gall bladder ever, for cause any (score 2 if > 1 site) 
 Mesenteric insufficiency         1 
 Chronic peritonitis         1 
 Stricture or upper gastrointestinal tract surgery ever    1 
Musculoskeletal 
 Muscle atrophy or weakness        1 
 Deforming or erosive arthritis (including reducible deformities,  1 
 excluding avascular necrosis) 
 Osteoporosis with fracture or vertebral collapse (excluding avascular 1 
 necrosis) 
 Avascular necrosis (score 2 if > 1)       1(2) 
 Osteomyelitis          1 
Skin 
 Scarring chronic alopecia        1 
 Extensive scarring or panniculum other than scalp and pulp space  1 
 Skin ulceration (excluding thrombosis) for > 6 months    1 
Premature gonadal failure         1 
Diabetes (regardless of treatment)       1 
Malignancy (exclude dysplasia) (score 2 if > 1 site)      1(2) 
 
*Damage (nonreversible change, not related to active inflammation) occurring 
since onset of lupus, ascertained byclinical assessment and present for at least 6 
months unless otherwise stated. Repeat episodes must occur 6 monthsapart to 
score 2. The same lesion cannot be scored twice. 
 
 
 
